Axel Knebel who, until recently, was a Postdoctoral Fellow in Philip Cohen's group, has set up a new company called Kinasource, which aims to exploit commercially the new method for identifying substrates of protein kinases (termed KESTREL, EMBO Vol 20, No 16, pp 4360-4369, 2001) that he developed in Philip's lab. The new company will be based on the 4th floor of the Medical Sciences Institute at Dundee for the next 15 months before moving to other premises in the city.